|
1
|
Wi DH, Cha JH and Jung YS: Mucin in
cancer: A stealth cloak for cancer cells. BMB Rep. 54:344–355.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Xu F, Liu F, Zhao H, An G and Feng G:
Prognostic significance of mucin antigen MUC1 in various human
epithelial cancers: A meta-analysis. Medicine (Baltimore).
94(e2286)2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bose M, Grover P, Sanders AJ, Zhou R,
Ahmad M, Shwartz S, Lala P, Nath S, Yazdanifar M, Brouwer C and
Mukherjee P: Overexpression of MUC1 induces non-canonical TGF-β
signaling in pancreatic ductal adenocarcinoma. Front Cell Dev Biol.
10(821875)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Khodabakhsh F, Merikhian P, Eisavand MR
and Farahmand L: Crosstalk between MUC1 and VEGF in angiogenesis
and metastasis: A review highlighting roles of the MUC1 with an
emphasis on metastatic and angiogenic signaling. Cancer Cell Int.
21(200)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Supruniuk K and Radziejewska I: MUC1 is an
oncoprotein with a significant role in apoptosis (Review). Int J
Oncol. 59(68)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen W, Zhang Z, Zhang S, Zhu P, Ko JK and
Yung KK: MUC1: Structure, function, and clinic application in
epithelial cancers. Int J Mol Sci. 22(6567)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Beatty PL and Finn OJ: Preventing cancer
by targeting abnormally expressed self-antigens: MUC1 vaccines for
prevention of epithelial adenocarcinomas. Ann N Y Acad Sci.
1284:52–56. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Guo M, You C and Dou J: Role of
transmembrane glycoprotein mucin 1 (MUC1) in various types of
colorectal cancer and therapies: Current research status and
updates. Biomed Pharmacother. 107:1318–1325. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cascio S and Finn OJ: Intra- and
extra-cellular events related to altered glycosylation of MUC1
promote chronic inflammation, tumor progression, invasion, and
metastasis. Biomolecules. 6(39)2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gao T, Cen Q and Lei H: A review on
development of MUC1-based cancer vaccine. Biomed Pharmacother.
132(110888)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li W, Han Y, Sun C, Li X, Zheng J, Che J,
Yao X and Kufe D: Novel insights into the roles and therapeutic
implications of MUC1 oncoprotein via regulating proteins and
non-coding RNAs in cancer. Theranostics. 12:999–1011.
2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hagiwara M, Fushimi A, Bhattacharya A,
Yamashita N, Morimoto Y, Oya M, Withers HG, Hu Q, Liu T, Liu S, et
al: MUC1-C integrates type II interferon and chromatin remodeling
pathways in immunosuppression of prostate cancer. Oncoimmunology.
11(2029298)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yasumizu Y, Rajabi H, Jin C, Hata T,
Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, et al: MUC1-C
regulates lineage plasticity driving progression to neuroendocrine
prostate cancer. Nat Commun. 11(338)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hosseinzadeh A, Merikhian P, Naseri N,
Eisavand MR and Farahmand L: MUC1 is a potential target to overcome
trastuzumab resistance in breast cancer therapy. Cancer Cell Int.
22(110)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Utispan K and Koontongkaew S: Mucin 1
regulates the hypoxia response in head and neck cancer cells. J
Pharmacol Sci. 147:331–339. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Quoix E, Lena H, Losonczy G, Forget F,
Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A,
Kazarnowicz A, et al: TG4010 immunotherapy and first-line
chemotherapy for advanced non-small-cell lung cancer (TIME):
Results from the phase 2b part of a randomised, double-blind,
placebo-controlled, phase 2b/3 trial. Lancet Oncol. 17:212–223.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ning Y, Zheng H, Zhan Y, Liu S, Yang Y,
Zang H, Luo J, Wen Q and Fan S: Comprehensive analysis of the
mechanism and treatment significance of Mucins in lung cancer. J
Exp Clin Cancer Res. 39(162)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kwan TY and Chowdhury EH: Clinical
outcomes of chemotherapeutic molecules as single and multiple
agents in advanced non-small-cell lung carcinoma (NSCLC) patients.
Medicina (Kaunas). 57(1252)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kaira K, Nakagawa K, Ohde Y, Okumura T,
Takahashi T, Murakami H, Endo M, Kondo H, Nakajima T and Yamamoto
N: Depolarized MUC1 expression is closely associated with hypoxic
markers and poor outcome in resected non-small cell lung cancer.
Int J Surg Pathol. 20:223–232. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H
and Rong T: Expression and prognostic relevance of MUC1 in stage IB
non-small cell lung cancer. Med Oncol. 28 (Suppl 1):S596–S604.
2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Palladino P, Papi F, Minunni M, Nativi C
and Scarano S: Structurally constrained MUC1-tn mimetic antigen as
template for molecularly imprinted polymers (MIPs): A promising
tool for cancer diagnostics. Chempluschem.
87(e202200068)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kato T, Ujiie H, Hatanaka KC, Nange A,
Okumura A, Tsubame K, Naruchi K, Sato M, Kaga K, Matsuno Y, et al:
A novel Tn antigen epitope-recognizing antibody for MUC1 predicts
clinical outcome in patients with primary lung adenocarcinoma.
Oncol Lett. 21(202)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xie Q, Zhao S, Liu W, Cui Y, Li F, Li Z,
Guo T, Yu W, Guo W, Deng W and Gu C: YBX1 enhances metastasis and
stemness by transcriptionally regulating MUC1 in lung
adenocarcinoma. Front Oncol. 11(702491)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liu S, Zhang X, Jiang Q and Liang T:
Detection of circulating natural antibodies against CD25, MUC1, and
VEGFR1 for early diagnosis of non-small cell lung cancer. FEBS Open
Bio. 10:1288–1294. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Warawdekar UM, Sirajuddin MM, Pramesh CS
and Mistry RC: An approach of selecting appropriate markers from
the primary tumor to enable detection of circulating tumor cells in
patients with non-small cell lung cancer. J BUON. 20:782–790.
2015.PubMed/NCBI
|
|
26
|
Li J, Hu YM, Du YJ, Zhu LR, Qian H, Wu Y
and Shi WL: Expressions of MUC1 and vascular endothelial growth
factor mRNA in blood are biomarkers for predicting efficacy of
gefitinib treatment in non-small cell lung cancer. BMC Cancer.
14(848)2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Savarese-Brenner B, Heugl M, Rath B,
Schweizer C, Obermayr E, Stickler S and Hamilton G: MUC1 and CD147
are promising markers for the detection of circulating tumor cells
in small cell lung cancer. Anticancer Res. 42:429–439.
2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Borri F and Granaglia A: Pathology of
triple negative breast cancer. Semin Cancer Biol. 72:136–145.
2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Siroy A, Abdul-Karim FW, Miedler J, Fong
N, Fu P, Gilmore H and Baar J: MUC1 is expressed at high frequency
in early-stage basal-like triple-negative breast cancer. Hum
Pathol. 44:2159–2166. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Maeda T, Hiraki M, Jin C, Rajabi H, Tagde
A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, et al: MUC1-C
induces PD-L1 and immune evasion in triple-negative breast cancer.
Cancer Res. 78:205–215. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yamashita N, Long M, Fushimi A, Yamamoto
M, Hata T, Hagiwara M, Bhattacharya A, Hu Q, Wong KK, Liu S and
Kufe D: MUC1-C integrates activation of the IFN-gamma pathway with
suppression of the tumor immune microenvironment in triple-negative
breast cancer. J Immunother Cancer. 9(e002115)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Laidi F, Bouziane A, Errachid A and Zaoui
F: Usefulness of salivary and serum auto-antibodies against tumor
biomarkers HER2 and MUC1 in breast cancer screening. Asian Pac J
Cancer Prev. 17:335–339. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cheng JP, Yan Y, Wang XY, Lu YL, Yuan YH,
Jia J and Ren J: MUC1-positive circulating tumor cells and MUC1
protein predict chemotherapeutic efficacy in the treatment of
metastatic breast cancer. Chin J Cancer. 30:54–61. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jing X, Liang H, Hao C, Yang X and Cui X:
Overexpression of MUC1 predicts poor prognosis in patients with
breast cancer. Oncol Rep. 41:801–810. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li J, Liu L, Feng Z, Wang X, Huang Y, Dai
H, Zhang L, Song F, Wang D, Zhang P, et al: Tumor markers CA15-3,
CA125, CEA and breast cancer survival by molecular subtype: A
cohort study. Breast Cancer. 27:621–630. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gaitskell K, Hermon C, Barnes I, Pirie K,
Floud S, Green J, Beral V and Reeves GK: Million Women Study
Collaborators. Ovarian cancer survival by stage, histotype, and
pre-diagnostic lifestyle factors, in the prospective UK million
women study. Cancer Epidemiol. 76(102074)2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ma Q, Song J, Wang S and He N: MUC1
regulates AKT signaling pathway by upregulating EGFR expression in
ovarian cancer cells. Pathol Res Pract. 224(153509)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Budiu RA, Mantia-Smaldone G, Elishaev E,
Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP and Vlad AM:
Soluble MUC1 and serum MUC1-specific antibodies are potential
prognostic biomarkers for platinum-resistant ovarian cancer. Cancer
Immunol Immunother. 60:975–984. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins
AC and Li Y: Expression of MUC1 in primary and metastatic human
epithelial ovarian cancer and its therapeutic significance. Gynecol
Oncol. 105:695–702. 2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Barani M, Bilal M, Sabir F, Rahdar A and
Kyzas GZ: Nanotechnology in ovarian cancer: Diagnosis and
treatment. Life Sci. 266(118914)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Hu XF, Yang E, Li J and Xing PX: MUC1
cytoplasmic tail: A potential therapeutic target for ovarian
carcinoma. Expert Rev Anticancer Ther. 6:1261–1271. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Elvevi A, Laffusa A, Scaravaglio M, Rossi
RE, Longarini R, Stagno AM, Cristoferi L, Ciaccio A, Cortinovis DL,
Invernizzi P and Massironi S: Clinical treatment of
cholangiocarcinoma: An updated comprehensive review. Ann Hepatol.
27(100737)2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Park SY, Roh SJ, Kim YN, Kim SZ, Park HS,
Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression of MUC1,
MUC2, MUC5AC and MUC6 in cholangiocarcinoma: Prognostic impact.
Oncol Rep. 22:649–657. 2009.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Mall AS, Tyler MG, Ho SB, Krige JEJ, Kahn
D, Spearman W, Myer L and Govender D: The expression of MUC mucin
in cholangiocarcinoma. Pathol Res Pract. 206:805–809.
2010.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chen FY, Zhou C, Zhang XY, Zhou KQ, Peng
YF, Yu L, Fan J, Zhou J, Hu J and Wang Z: Integrated Bioinformatics
analysis and clinical validation reveals that high expression of
mucin 1 in intrahepatic cholangiocarcinoma predicts recurrence
after curative resection. Exp Ther Med. 20(50)2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Matsumura N, Yamamoto M, Aruga A, Takasaki
K and Nakano M: Correlation between expression of MUC1 core protein
and outcome after surgery in mass-forming intrahepatic
cholangiocarcinoma. Cancer. 94:1770–1776. 2002.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Supimon K, Sangsuwannukul T, Sujjitjoon J,
Phanthaphol N, Chieochansin T, Poungvarin N, Wongkham S, Junking M
and Yenchitsomanus PT: Anti-mucin 1 chimeric antigen receptor T
cells for adoptive T cell therapy of cholangiocarcinoma. Sci Rep.
11(6276)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Bosch DE, Salipante SJ, Schmidt RA,
Swanson PE, Bryan A, SenGupta DJ, Truong CD and Yeh MM:
Neutrophilic inflammation in gallbladder carcinoma correlates with
patient survival: A case-control study. Ann Diagn Pathol.
56(151845)2022.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Garcia P, Bizama C, Rosa L, Espinoza JA,
Weber H, Cerda-Infante J, Sánchez M, Montecinos VP, Lorenzo-Bermejo
J, Boekstegers F, et al: Functional and genomic characterization of
three novel cell lines derived from a metastatic gallbladder cancer
tumor. Biol Res. 53(13)2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Bhoge A, Khandeparkar SGS, Joshi AR,
Gogate B, Kulkarni MM and Bhayekar P: Immunohistochemical study of
MUC1 and MUC5AC expression in gall bladder lesions. J Clin Diagn
Res. 11:EC12–EC16. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Xiong L, Yang Z, Yang L, Liu J and Miao X:
Expressive levels of MUC1 and MUC5AC and their clinicopathologic
significances in the benign and malignant lesions of gallbladder. J
Surg Oncol. 105:97–103. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kaur S, Momi N, Chakraborty S, Wagner DG,
Horn AJ, Lele SM, Theodorescu D and Batra SK: Altered expression of
transmembrane mucins, MUC1 and MUC4, in bladder cancer:
Pathological implications in diagnosis. PLoS One.
9(e92742)2014.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Stojnev S, Ristic-Petrovic A, Velickovic
LJ, Krstic M, Bogdanovic D, Khanh DT, Ristic A, Conic I and
Stefanovic V: Prognostic significance of mucin expression in
urothelial bladder cancer. Int J Clin Exp Pathol. 7:4945–4958.
2014.PubMed/NCBI
|
|
54
|
Gonul II, Cakir A and Sozen S:
Immunohistochemical expression profiles of MUC1 and MUC2 mucins in
urothelial tumors of bladder. Indian J Pathol Microbiol.
61:350–355. 2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tao TT, Chen J, Hu Q, Huang XZ, Fu J, Lv
BD and Duan Y: Urothelial carcinoma of the bladder with abundant
myxoid stroma: A case report and literature review. Medicine
(Baltimore). 99(e21204)2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Shigeta K, Hasegawa M, Kikuchi E, Yasumizu
Y, Kosaka T, Mizuno R, Mikami S, Miyajima A, Kufe D and Oya M: Role
of the MUC1-C oncoprotein in the acquisition of cisplatin
resistance by urothelial carcinoma. Cancer Sci. 111:3639–3652.
2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer.
1873(188314)2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han
W and Zhang YQ: Expression of MUC1 and its significance in
hepatocellular and cholangiocarcinoma tissue. World J
Gastroenterol. 11:4661–4666. 2005.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Ichikawa T, Yamamoto T, Uenishi T, Tanaka
H, Takemura S, Ogawa M, Tanaka S, Suehiro S, Hirohashi K and Kubo
S: Clinicopathological implications of immunohistochemically
demonstrated mucin core protein expression in hepatocellular
carcinoma. J Hepatobiliary Pancreat Surg. 13:245–251.
2006.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Jiang QL, Feng SJ, Yang ZY, Xu Q and Wang
SZ: CircHECTD1 up-regulates mucin 1 expression to accelerate
hepatocellular carcinoma development by targeting microRNA-485-5p
via a competing endogenous RNA mechanism. Chin Med J (Engl).
133:1774–1785. 2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Morari EC, Silva JR, Guilhen AC, Cunha LL,
Marcello MA, Soares FA, Vassallo J and Ward LS: Muc-1 expression
may help characterize thyroid nodules but does not predict
patients' outcome. Endocr Pathol. 21:242–249. 2010.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Zhan XX, Zhao B, Diao C, Cao Y and Cheng
RC: Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in
papillary thyroid carcinomas. Endocr Pathol. 26:21–26.
2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Hu YJ, Luo XY, Yang Y, Chen CY, Zhang ZY
and Guo X: Characterization and significance of MUC1 and c-myc
expression in elderly patients with papillary thyroid carcinoma.
Genet Mol Res. 14:15325–15330. 2015.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Baloch ZW, Asa SL, Barletta JA, Ghossein
RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M,
Tallini G and Mete O: Overview of the 2022 WHO classification of
thyroid neoplasms. Endocr Pathol. 33:27–63. 2022.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Baek SK, Woo JS, Kwon SY, Lee SH, Chae YS
and Jung KY: Prognostic significance of the MUC1 and MUC4
expressions in thyroid papillary carcinoma. Laryngoscope.
117:911–916. 2007.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Guo M, Luo B, Pan M, Li M, Xu H, Zhao F
and Dou J: Colorectal cancer stem cell vaccine with high expression
of MUC1 serves as a novel prophylactic vaccine for colorectal
cancer. Int Immunopharmacol. 88(106850)2020.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Guo M, You C, Dong W, Luo B, Wu Y, Chen Y,
Li J, Pan M, Li M, Zhao F and Dou J: The surface dominant antigen
MUC1 is required for colorectal cancer stem cell vaccine to exert
anti-tumor efficacy. Biomed Pharmacother.
132(110804)2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Wang HS and Wang LH: The expression and
significance of Gal-3 and MUC1 in colorectal cancer and colon
cancer. Onco Targets Ther. 8:1893–1898. 2015.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Kasprzak A, Siodla E, Andrzejewska M,
Szmeja J, Seraszek-Jaros A, Cofta S and Szaflarski W: Differential
expression of mucin 1 and mucin 2 in colorectal cancer. World J
Gastroenterol. 24:4164–4177. 2018.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Hazgui M, Weslati M, Boughriba R, Ounissi
D, Bacha D and Bouraoui S: MUC1 and MUC5AC implication in Tunisian
colorectal cancer patients. Turk J Med Sci. 51:309–318.
2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Niv Y and Rokkas T: Mucin expression in
colorectal cancer (CRC): Systematic review and meta-analysis. J
Clin Gastroenterol. 53:434–440. 2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Schimanski CC, Kasper S, Hegewisch-Becker
S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M,
Öllinger R, Lordick F, et al: Adjuvant MUC vaccination with
tecemotide after resection of colorectal liver metastases: A
randomized, double-blind, placebo-controlled, multicenter AIO phase
II trial (LICC). Oncoimmunology. 9(1806680)2020.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Shimada M, Tsuji K, Shigeta S, Nagai T,
Watanabe Z, Tokunaga H, Kigawa J and Yaegashi N: Rethinking the
significance of surgery for uterine cervical cancer. J Obstet
Gynaecol Res. 48:576–586. 2022.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Togami S, Nomoto M, Higashi M, Goto M,
Yonezawa S, Tsuji T, Batra SK and Douchi T: Expression of mucin
antigens (MUC1 and MUC16) as a prognostic factor for mucinous
adenocarcinoma of the uterine cervix. J Obstet Gynaecol Res.
36:588–597. 2010.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Gardner AB, Charo LM, Mann AK, Kapp DS,
Eskander RN and Chan JK: Ovarian, uterine, and cervical cancer
patients with distant metastases at diagnosis: Most common
locations and outcomes. Clin Exp Metastasis. 37:107–113.
2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Samouëlian V, Mechtouf N, Leblanc E,
Cardin GB, Lhotellier V, Querleu D, Révillion F and Rodier F:
Sensitive molecular detection of small nodal metastasis in uterine
cervical cancer using HPV16-E6/CK19/MUC1 cancer biomarkers.
Oncotarget. 9:21641–21654. 2018.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Cai J, Chen H, Lu M, Zhang Y, Lu B, You L,
Zhang T, Dai M and Zhao Y: Advances in the epidemiology of
pancreatic cancer: Trends, risk factors, screening, and prognosis.
Cancer Lett. 520:1–11. 2021.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Wang S, You L, Dai M and Zhao Y: Mucins in
pancreatic cancer: A well-established but promising family for
diagnosis, prognosis and therapy. J Cell Mol Med. 24:10279–10289.
2020.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Fu X, Tang N, Xie WQ, Mao L and Qiu YD:
MUC1 promotes glycolysis through inhibiting BRCA1 expression in
pancreatic cancer. Chin J Nat Med. 18:178–185. 2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Sierzega M, Mlynarski D, Tomaszewska R and
Kulig J: Semiquantitative immunohistochemistry for mucin (MUC1,
MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal
cell adenocarcinoma improves diagnostic and prognostic performance.
Histopathology. 69:582–591. 2016.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Maleki F, Rezazadeh F and Varmira K:
MUC1-targeted radiopharmaceuticals in cancer imaging and therapy.
Mol Pharm. 18:1842–1861. 2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Alirezapour B, Ashkezari MD, Fini MM,
Rasaee MJ, Mohammadnejad J, Paknejad M, Maadi E, Yousefnia H and
Zolghadri S: Preparation and preclinical characterization of
(111)In-DTPA-Anti-MUC1 as a radioimmunoconjugate for diagnosis of
breast cancer by single-photon emission computed tomography. J
Cancer Res Ther. 18:158–167. 2022.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Stergiou N, Nagel J, Pektor S, Heimes AS,
Jäkel J, Brenner W, Schmidt M, Miederer M, Kunz H, Roesch F and
Schmitt E: Evaluation of a novel monoclonal antibody against
tumor-sassociated MUC1 for diagnosis and prognosis of breast
cancer. Int J Med Sci. 16:1188–1198. 2019.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Pierga JY, Bidard FC, Denis MG and de
Cremoux P: Prognostic value of peripheral blood double detection of
CK19 and MUC1 mRNA positive cells detected by RT-quantitative PCR
in 94 breast cancer patients with a follow up of 9 years. Mol
Oncol. 1:267–268. 2007.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Liu C, Xie Y, Sun B, Geng F, Zhang F, Guo
Q, Wu H, Yu B, Wu J, Yu X, et al: MUC1- and survivin-based DNA
vaccine combining immunoadjuvants CpG and interleukin-2 in a
bicistronic expression plasmid generates specific immune responses
and antitumour effects in a murine colorectal carcinoma model.
Scand J Immunol. 87:63–72. 2018.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Ruan J, Duan Y, Li F and Wang Z: Enhanced
synergistic anti-Lewis lung carcinoma effect of a DNA vaccine
harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an
adjuvant. Clin Exp Pharmacol Physiol. 44:71–78. 2017.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Gong YF, Zhou QB, Liao YD, Mai C, Chen TJ,
Tang YQ and Chen RF: Optimized construction of MUC1-VNTRn DNA
vaccine and its anti-pancreatic cancer efficacy. Oncol Lett.
13:2198–2206. 2017.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Ogasawara M, Miyashita M, Yamagishi Y and
Ota S: Dendritic cell vaccination combined with a conventional
chemotherapy for patients with relapsed or advanced pancreatic
ductal adenocarcinoma: A single-center phase I/II trial. Ther Apher
Dial. 25:415–424. 2021.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Ota S, Miyashita M, Yamagishi Y and
Ogasawara M: Baseline immunity predicts prognosis of pancreatic
cancer patients treated with WT1 and/or MUC1 peptide-loaded
dendritic cell vaccination and a standard chemotherapy. Hum Vaccin
Immunother. 17:5563–5572. 2021.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Tosch C, Bastien B, Barraud L, Grellier B,
Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K and
Préville X: Viral based vaccine TG4010 induces broadening of
specific immune response and improves outcome in advanced NSCLC. J
Immunother Cancer. 5(70)2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Glaffig M, Stergiou N, Hartmann S, Schmitt
E and Kunz H: A synthetic MUC1 anticancer vaccine containing
mannose ligands for targeting macrophages and dendritic cells.
ChemMedChem. 13:25–29. 2018.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Hu B, Wang J, Guo Y, Chen T, Ni W, Yuan H,
Zhang N, Xie F and Tai G: Pre-clinical toxicity and immunogenicity
evaluation of a MUC1-MBP/BCG anti-tumor vaccine. Int
Immunopharmacol. 33:108–118. 2016.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Zhang H, Zhao H, He X, Xi F and Liu J:
JAK-STAT domain enhanced MUC1-CAR-T cells induced esophageal cancer
elimination. Cancer Manag Res. 12:9813–9824. 2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Mei Z, Zhang K, Lam AK, Huang J, Qiu F,
Qiao B and Zhang Y: MUC1 as a target for CAR-T therapy in head and
neck squamous cell carinoma. Cancer Med. 9:640–652. 2020.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Zhou R, Yazdanifar M, Roy LD, Whilding LM,
Gavrill A, Maher J and Mukherjee P: CAR T cells targeting the tumor
MUC1 glycoprotein reduce triple-negative breast cancer growth.
Front Immunol. 10(1149)2019.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Pang L, Wang J, Fan Y, Xu R, Bai Y and Bai
L: Correlations of TNM staging and lymph node metastasis of gastric
cancer with MRI features and VEGF expression. Cancer Biomark.
23:53–59. 2018.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Jeong O, Jung MR and Kang JH: Prognostic
value of the anatomic region of metastatic lymph nodes in the
current TNM staging of gastric cancer. J Gastric Cancer.
21:236–245. 2021.PubMed/NCBI View Article : Google Scholar
|
